EMD Serono
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, EMD Serono sits in the top decile of US sponsors by registered trial count (#303 of 15,742 sponsors by registered trial count).
EMD Serono: 71 sponsored US clinical trials, none currently recruiting.
EMD Serono sponsors 71 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 48 completed. 24 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available, with 1 trials.
Top-decile sponsor footprint
EMD Serono ranks in the top decile of sponsors by registered trial count (#303 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
48 of 71 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
71 total, page 2 of 2
RNF and Betaseron® Tolerability Study
NCT00428584
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
NCT01080664
AS703569 Phase I in Patients With Solid Tumours
NCT00391521
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
NCT00328926
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
NCT00111839
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
NCT00132522
Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction
NCT00213148
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
NCT01077960
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
NCT00109733
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
NCT00110396
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
NCT00093964
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
NCT00105521
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
NCT00105508
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
NCT00090129
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
NCT00082628
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
NCT00078338
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
NCT00073541
Rebif® Pregnancy Registry
NCT00338741
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
NCT00314288
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
NCT00016237
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
NCT00262314
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 24 |
| Phase 3 | 17 |
| Phase 4 | 7 |
How the EMD Serono early-phase archive is shaped
71 indexed studies, none listed as recruiting (0% open); 48 completed (68%).
Phase mix: 24 late (III/IV) vs 40 early (I/II) (early-phase heavy).
Top condition: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available (1 trial), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
EMD Serono: archived-pipeline peers nationwide
Peers matched on 71 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
EMD Serono sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 71 archived trials
- CSL Behring · 71 trials · 17% recruiting
- Nova Southeastern University · 71 trials · 21% recruiting
- H. Lundbeck A/S · 72 trials · 7% recruiting
- Smith & Nephew · 72 trials · 4% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this EMD Serono page
71 registered trials is a research-attention snapshot, not an endorsement of EMD Serono or any single study.
- None of EMD Serono's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available is the condition EMD Serono studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
EMD Serono pipeline card: 71 registered trials from official public datasets.Report a data error.